Navigation Links
-- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
Date:6/17/2010

www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause Neurocrine's actual results to differ materially from those indicated in the forward looking statements are risks and uncertainties associated with Neurocrine's business and finances and research programs in general including, but not limited to, risk and uncertainties associated with, or arising out of, drug discovery, pre-clinical and clinical development of products and specifically risk that the GPR119 agonist program may not generate any development candidates that lead to clinical testing or commercial products; risk that GPR119 agonist compounds will not prove efficacious for the treatment of Type II diabetes; risk relating to Neurocrine's reliance on its collaborator for GPR119 agonist product development and commercialization; risk that Neurocrine could fail to meet its obligations under the GPR119 agonist program collaboration agreement which would cause it to forfeit certain rights and/or reduce future product payments; uncertainties relating to patent protection for GPR119 agonist compounds and intellectual property rights of third parties in the GPR119 agonist field; impact of competitive products and technological changes that may limit demand for Neurocrine's products; and the other risks described in Neurocrine's report on Form 10-K for the year ended December 31, 2009 and most recent report on Form 10-Q filed for the first quarter ended, March 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
2. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
3. Neurocrine Biosciences, Inc. Prices Common Stock Offering
4. Neurocrine Announces Proposed Public Offering of Common Stock
5. Neurocrine Advances VMAT2 Inhibitor Program
6. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Neurocrine Biosciences Reports Third Quarter 2009 Results
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
9. Neurocrine Biosciences Presents Elagolix Data
10. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
(Date:9/16/2014)... Sept. 16, 2014 Surgeons at The Children,s ... a case report the first successful use of a ... year-old boy with failing Fontan circulation to bridge him ... 3 years old, the patient received a Fontan circulation ... single ventricle. "The Fontan operation is the final planned ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
... June 20 GlaxoSmithKline,(NYSE: GSK ) today ... has extended the priority review period for PROMACTA(R),(eltrombopag) ... chronic idiopathic thrombocytopenic purpura, as they require more ... Fee action date has,been extended to September 19, ...
Cached Medicine Technology:PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5GSK Update on FDA Review of Promacta(R) (Eltrombopag) 2
(Date:9/16/2014)... hold great promise in helping people to reach ... devices help the wearers improve their wellness by ... information is organized into companion computer programs and ... quickly growing market for these devices, researchers at ... analyzed 13 of these activity monitors, such as ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Although magnesium sulfate is ... preterm delivery, new research suggests it won,t provide any ... effects of magnesium sulfate given to pregnant women, researchers ... behavioral, growth or functional outcomes among those children when ... old. The new findings don,t negate the fact ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... September 16, 2014 Programs and policies ... hundreds of billions of dollars in savings for the ... the Commonwealth Fund. To help spur these types of ... to 10 collaborative groups from across the country to ... http://bit.ly/1wo4gsa ) - a handbook designed to assist groups ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Who:, The ... Anschutz Medical Campus and Children’s Hospital Colorado ... is the country’s leading pulmonary hypertension association that works to ... a disease of the lungs that affects the functioning of ... treatment, mean survivability is only 2.8 years. , What:, ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... June 30 Standard & Poor,s will make the,following changes ... the,close of trading on Wednesday, July 2:, -- S&P ... replace Getty Images Inc. (NYSE: GYI ) in the ... replace IDEXX Laboratories in the S&P,SmallCap 600. Getty Images is ...
... findings as fact , , MONDAY, June 30 (HealthDay News) -- ... HDL cholesterol and loss of memory. , The study, which has ... percent increased loss of memory on a word test for those ... with the highest levels. By age 60, the rate of memory ...
... than placebo, one expert says , , MONDAY, June 30 ... of placing intravenous (IV) lines in children, Canadian researchers ... by 34 percent in children getting IV lines when ... rate of inserting the lines, said lead researcher Dr. ...
... for two adults? Experts consider this question alongside new ... Liver Transplantation , a journal by John Wiley ... Wiley Interscience ( www.interscience.wiley.com ). , The shortage of ... increase opportunities for those in need of a transplant. ...
... researchers at the Ocean University of China has developed and ... can accurately measure wind speed and direction over large areas ... weather forecasting and sports. , As described in the ... published by the Optical Society, the mobile lidar station can ...
... June 30 Robbins & Myers, Inc.,(NYSE: RBN ... for the third quarter,results conference call scheduled today, June ... or 1-617-614-3525,with ID# 84552408. Replays of the call can ... # 63192398., Robbins & Myers, Inc. is a ...
Cached Medicine News:Health News:Standard & Poor's Announces Changes to U.S. Indices 2Health News:Standard & Poor's Announces Changes to U.S. Indices 3Health News:Research Links Low HDL Levels With Memory Loss 2Health News:Spray Cuts Kids' Pain When Getting IVs 2Health News:Experts examine challenges of split liver transplantation 2Health News:New technology may help Olympic sailing 2
19 Gauge. Reusable. Block of 4 each....
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 23 gauge, stainless steel probes with blunt tips. Probes are 18 cm (7.0 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto the ...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: